| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5656650 | ABBVIE | Angiotensin II receptor blocking compositions |
Aug, 2014
(9 years ago) | |
Teveten Hct is owned by Abbvie.
Teveten Hct contains Eprosartan Mesylate; Hydrochlorothiazide.
Teveten Hct has a total of 1 drug patent out of which 1 drug patent has expired.
Expired drug patents of Teveten Hct are:
- US5656650
Teveten Hct was authorised for market use on 01 November, 2001.
Teveten Hct is available in tablet;oral dosage forms.
Teveten Hct can be used as treatment of hypertension.
The generics of Teveten Hct are possible to be released after 12 August, 2014.
Drugs and Companies using EPROSARTAN MESYLATE; HYDROCHLOROTHIAZIDE ingredient
Market Authorisation Date: 01 November, 2001
Treatment: Treatment of hypertension
Dosage: TABLET;ORAL
More Information on Dosage
TEVETEN HCT family patents
